Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Neurodevelopmental Outcome of Prematurely Born Children Treated With Recombinant Human Erythropoietin in Infancy

Journal of Perinatology volume 19, pages 403–406 (1999)Cite this article

Abstract

OBJECTIVE:

To compare the neurodevelopmental outcome of premature infants treated with recombinant human erythropoietin with that of control infants.

STUDY DESIGN:

A total of 20 treated infants and 20 control infants who had completed randomized, double-blind, placebo-controlled studies of recombinant human erythropoietin as treatment for anemia of prematurity were followed for growth and developmental outcome in an intensive care nursery follow-up program. Infants were assessed by standard developmental tests.

RESULTS:

No differences were found between groups for neurologic outcome, cognitive outcome, or growth patterns. All infants treated with recombinant human erythropoietin were neurologically normal. The rate of cognitive deficits was similar in the two groups.

CONCLUSION: In this small sample we did not see differences in neurodevelopmental outcome between infants treated with recombinant human erythropoietin and control infants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Division of Neonatology (C. H. L., Department of Pediatrics, Pediatric Clinical Research Center (N. R. N.) and Cardiovascular Research Institute (R. H. P.), R. E. P., R. H. P.), University of California, San Francisco, CA

    Nancy R Newton RN MS(c), Carol H Leonard PhD, Robert E Piecuch MD, Roderic H Phibbs MD & Roderic H Phibbs MD

Authors
  1. Nancy R Newton RN MS(c)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol H Leonard PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert E Piecuch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roderic H Phibbs MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by National Institutes of Health GrantM01RR01271; Pediatric Clinical Research Center, University ofCalifornia, San Francisco. The controlled trials of rHuEPO treatmentwere also supported in part by the R. W. Johnson PharmaceuticalResearch Institute (Raritan, NJ).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newton, N., Leonard, C., Piecuch, R. et al. Neurodevelopmental Outcome of Prematurely Born Children Treated With Recombinant Human Erythropoietin in Infancy. J Perinatol 19, 403–406 (1999). https://doi.org/10.1038/sj.jp.7200244

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7200244

This article is cited by

Search

Advanced search

Quick links